Markets

Zoetis (ZTS) Declares 14.5% Hike in Quarterly Dividend

Zoetis Inc.ZTS declared an increase of 14.5% in its quarterly dividend. The company announced a dividend of $0.095 per share for the first quarter of 2016, payable on Mar 1, 2016, to shareholders of record as on Jan 21, 2016. This represents an increase from $0.083 per share paid in each of the previous four quarters.

The new quarterly dividend comes to about 38 cents per share on a yearly basis, reflecting a forward yield of nearly 0.8% based on the raised dividend and the stock's last closing price of $47.09 (Dec 16, 2015).

The increase in dividend is in line with the company's strategy of returning excess capital to shareholders. In Dec 2014, the board of directors at Zoetis approved a 15% increase in the quarterly dividend to $0.083 per share. We are encouraged by the company's policy to reward shareholders through regular dividends.

Meanwhile, the company continues to pursue lucrative internal and external growth opportunities. Zoetis acquired Abbott Laboratories' ABT animal health assets for $255 million. This business is focused on the veterinary surgical market. It will strengthen Zoetis' pain portfolio and sedation product portfolio and complement its diagnostic business. The company also acquired PHARMAQ in a bid to strengthen its core livestock business. We expect to see more of such acquisitions/deals at Zoetis in the near future, as the company continues to focus on its strategy of acquiring complementary businesses and products.

Zoetis currently carries a Zacks Rank #3 (Hold). A couple of other well-ranked stocks in the health care sector are Achillion Pharmaceuticals, Inc. ACHN and Corcept Therapeutics Incorporated CORT , both sporting a Zacks Rank #1 (Strong Buy).

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days.Click to get this free report >>

Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report

ABBOTT LABS (ABT): Free Stock Analysis Report

CORCEPT THERAPT (CORT): Free Stock Analysis Report

ACHILLION PHARM (ACHN): Free Stock Analysis Report

ZOETIS INC (ZTS): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

CORT ZTS ABT

Other Topics

Stocks

Latest Markets Videos

    Zacks

    Zacks is the leading investment research firm focusing on stock research, analysis and recommendations. In 1978, our founder discovered the power of earnings estimate revisions to enable profitable investment decisions. Today, that discovery is still the heart of the Zacks Rank. A wealth of resources for individual investors is available at www.zacks.com.

    Learn More